Loading stock data…
$22.26+0.73 (+3.39%)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Collegium Pharmaceutical, Inc. in the Healthcare sector is trading at $22.37 with a market capitalization of $916M. Wall Street consensus targets $49.00 (8 analysts), implying a +119.0% move over the next 12 months. The stock is currently near its 52-week low of $21.43, remaining 35.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $199.88M↑ | $193.52M↓ | $205.45M↓ | $209.36M↑ | $188.00M |
| Gross Profit | $110.29M↓ | $117.25M↓ | $128.38M↓ | $129.17M↑ | $108.38M |
| Operating Income | $3.70M↓ | $30.90M↓ | $60.74M↓ | $62.07M↑ | $34.75M |
| Net Income | -$15.05M↓ | $14.50M↓ | $16.96M↓ | $31.51M↑ | $11.98M |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicin...